
Hancock Jaffe Laboratories, Inc. Financial Statements 2011-2026 | HJLI
Annual Financial Statements Hancock Jaffe Laboratories, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
7.99 M | 9.61 M | 16.9 M | - | - | - | - | - | - | - |
Shares |
859 K | 630 K | 374 K | - | - | - | - | - | - | - |
Net Income |
-9.14 K | -7.63 M | -13 M | -7.79 M | -3.39 M | -1.6 M | - | - | - | - |
Revenue |
4.25 K | 31.2 K | 187 K | 422 K | 786 K | - | - | - | - | - |
EBITDA |
88.4 K | -6.69 M | -7.4 M | -5.96 M | -4.51 M | -1.16 M | - | - | - | - |
Operating Expenses |
9.14 K | 7.12 M | 7.72 M | 6.11 M | 4.63 M | 1.29 M | - | - | - | - |
General and Administrative Expenses |
4.88 K | 4.91 M | 6.48 M | 5.46 M | 4.63 M | 1.29 M | - | - | - | - |
All numbers in USD currency
Main types of financial statements Hancock Jaffe Laboratories, Inc. HJLIFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting Hancock Jaffe Laboratories, Inc. plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Alphatec Holdings
ATEC
|
$ 11.75 | -3.29 % | $ 1.76 B | ||
|
BioSig Technologies
BSGM
|
- | 37.08 % | $ 85.7 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
- | - | $ 1.77 B | ||
|
Axonics Modulation Technologies
AXNX
|
- | - | $ 3.31 B | ||
|
Delcath Systems
DCTH
|
$ 8.98 | -1.32 % | $ 322 M | ||
|
Lianluo Smart Limited
LLIT
|
- | 24.59 % | $ 44.8 M | ||
|
Aziyo Biologics
AZYO
|
- | 1.37 % | $ 20.5 M | ||
|
Acutus Medical
AFIB
|
- | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
- | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
- | -5.86 % | $ 30.6 M | ||
|
Second Sight Medical Products
EYES
|
- | -0.97 % | $ 54.4 M | ||
|
FONAR Corporation
FONR
|
$ 18.41 | 0.38 % | $ 121 M | ||
|
Conformis
CFMS
|
- | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | ||
|
Inogen
INGN
|
$ 6.32 | -2.02 % | $ 168 M | ||
|
Apollo Endosurgery
APEN
|
- | - | $ 475 M | ||
|
IRIDEX Corporation
IRIX
|
$ 1.35 | - | $ 21.8 M | ||
|
IRadimed Corporation
IRMD
|
$ 100.97 | 1.78 % | $ 1.28 B | ||
|
Avinger
AVGR
|
- | -20.74 % | $ 369 K | ||
|
CryoLife, Inc.
CRY
|
- | -4.14 % | $ 702 M | ||
|
LivaNova PLC
LIVN
|
$ 62.4 | -1.33 % | $ 3.4 B | ||
|
LENSAR
LNSR
|
$ 5.56 | -8.4 % | $ 64 M | ||
|
CHF Solutions, Inc.
CHFS
|
- | 1.15 % | $ 34.5 M | ||
|
AxoGen
AXGN
|
$ 32.61 | 2.71 % | $ 1.5 B | ||
|
CONMED Corporation
CNMD
|
$ 36.56 | -0.19 % | $ 1.13 B | ||
|
Medtronic PLC
MDT
|
$ 86.58 | -0.68 % | $ 111 B | ||
|
Soliton, Inc.
SOLY
|
- | -1.42 % | $ 435 M | ||
|
Itamar Medical Ltd.
ITMR
|
- | 0.03 % | $ 1.58 B | ||
|
NanoVibronix
NAOV
|
- | - | $ 1.08 M | ||
|
Electromed
ELMD
|
$ 24.7 | 0.86 % | $ 209 M | ||
|
Misonix, Inc.
MSON
|
- | - | $ 462 M | ||
|
Neovasc
NVCN
|
- | - | $ 111 M | ||
|
InspireMD
NSPR
|
$ 1.79 | 3.47 % | $ 115 M | ||
|
Orthofix Medical
OFIX
|
$ 11.72 | -1.26 % | $ 464 M | ||
|
Intersect ENT, Inc.
XENT
|
- | - | $ 955 M | ||
|
Cytosorbents Corporation
CTSO
|
$ 0.7 | 3.3 % | $ 38.1 M | ||
|
Aethlon Medical
AEMD
|
$ 2.16 | -6.09 % | $ 3.37 M | ||
|
Profound Medical Corp.
PROF
|
$ 5.15 | -4.63 % | $ 180 M | ||
|
BIOLASE
BIOL
|
- | -13.19 % | $ 166 K | ||
|
Penumbra
PEN
|
$ 334.17 | -0.41 % | $ 13 B | ||
|
AdaptHealth Corp.
AHCO
|
$ 11.48 | 10.7 % | $ 1.55 B | ||
|
Myomo
MYO
|
$ 0.7 | -1.83 % | $ 29.3 M | ||
|
Insulet Corporation
PODD
|
$ 225.5 | -0.7 % | $ 15.9 B | ||
|
Nano-X Imaging Ltd.
NNOX
|
$ 2.4 | -1.64 % | $ 141 M | ||
|
Invacare Corporation
IVC
|
- | - | $ 24.7 M | ||
|
EDAP TMS S.A.
EDAP
|
$ 3.91 | 4.83 % | $ 146 M | ||
|
Quanterix Corporation
QTRX
|
$ 3.82 | -3.05 % | $ 163 M | ||
|
OrthoPediatrics Corp.
KIDS
|
$ 15.91 | -3.4 % | $ 373 M | ||
|
Outset Medical
OM
|
$ 3.53 | -2.35 % | $ 53.7 K |